Illumina Inc
Research Illumina Inc (ILMN) on Bullrun: valuation model: 22.4% overvalued, market cap USD 41.78B, P/E 51.6. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerILMN
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryDiagnostics & Research
- CurrencyUSD
- Valuation signal22.4% overvalued
- Market capUSD 41.78B
- P/E51.6
- Financial periodQ1 2026
- RevenueUSD 1.09B
- Net incomeUSD 134.00M
- Free cash flowUSD 251.00M
- Gross margin66.1%
Valuation Snapshot
Bullrun's latest valuation model marks Illumina Inc as 22.4% overvalued; latest market cap is USD 41.78B; P/E is 51.6.
Peer valuation comparison
Latest P/E is 51.56x versus a Healthcare sector median of 24.6x (109.6% above).
Latest P/E is 51.56x versus a United States median of 23.85x (116.2% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 4.34B | USD 850.00M | USD 931.00M | 66.1% | 5.45 | USD 1.42B | USD 2.55B | USD 2.72B |
| FY2024 | USD 4.37B | -USD 1.22B | USD 709.00M | 65.4% | -7.69 | USD 1.13B | USD 2.62B | USD 2.37B |
| FY2023 | USD 4.50B | -USD 1.16B | USD 283.00M | 60.9% | -7.34 | USD 1.05B | USD 2.26B | USD 5.75B |
| FY2022 | USD 4.53B | USD 762.00M | USD 337.00M | 69.7% | 5.04 | USD 1.23B | USD 0 | USD 10.74B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 41.78B | 51.6 | n/a | n/a |
| 2025 | 2025-12-31 | USD 20.07B | 24.0 | n/a | n/a |
| 2024 | 2024-12-31 | USD 21.25B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 21.51B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 30.94B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 57.84B | 73.4 | n/a | n/a |
About Illumina Inc
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity;
ETFs that hold Illumina Inc
Illumina Inc is one of the ten largest holdings of 36 ETFs that investors in Europe can buy. The 8 most traded of them:
| ETF | Weight | TER |
|---|---|---|
| iShares S&P 500 Equal Weight UCITS ETF USD (Acc) | 0.28% | 0.15% |
| Invesco MSCI World Equal Weight UCITS ETF USD Accumulating | 0.11% | 0.20% |
| iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) | 2.70% | 0.35% |
| State Street SPDR S&P 400 US Mid Cap UCITS ETF | 0.91% | 0.30% |
| iShares Healthcare Innovation UCITS ETF USD (Acc) | 2.07% | 0.40% |
| L&G ROBO Global Robotics and Automation UCITS ETF | 1.92% | 0.80% |
| Invesco S&P 500 Equal Weight Index ETF Acc | 0.27% | 0.20% |
| ARK Genomic | 5.16% | 0.75% |
Compare every fund on the same index:
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Illumina Inc overvalued or undervalued?
Bullrun's valuation model currently marks Illumina Inc as 22.4% overvalued.
What is Illumina Inc's market cap?
Illumina Inc's market capitalization is USD 41.78B.
What is Illumina Inc's P/E ratio?
Illumina Inc's price-to-earnings (P/E) ratio is 51.6.
What does Illumina Inc do?
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.